REGENXBIO Inc. (RGNX) Hit 52-Week High

May 17, 2018 - By Paula Hilliard


The stock of REGENXBIO Inc. (NASDAQ:RGNX) hit a new 52-week high and has $49.85 target or 3.00 % above today’s $48.40 share price. The 6 months bullish chart indicates low risk for the $1.55B company. The 1-year high was reported on May, 17 by If the $49.85 price target is reached, the company will be worth $46.38 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 1.12% or $0.55 during the last trading session, reaching $48.4. About 264,924 shares traded. REGENXBIO Inc. (NASDAQ:RGNX) has risen 43.49% since May 17, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.

Analysts await REGENXBIO Inc. (NASDAQ:RGNX) to report earnings on August, 14. They expect $1.90 earnings per share, up 504.26 % or $2.37 from last year’s $-0.47 per share. RGNX’s profit will be $60.69M for 6.37 P/E if the $1.90 EPS becomes a reality. After $3.00 actual earnings per share reported by REGENXBIO Inc. for the previous quarter, Wall Street now forecasts -36.67 % negative EPS growth.

More notable recent REGENXBIO Inc. (NASDAQ:RGNX) news were published by: which released: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018, also with their article: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” published on May 16, 2018, published: “REGENXBIO: An Underappreciated Leader In Gene Editing” on April 21, 2018. More interesting news about REGENXBIO Inc. (NASDAQ:RGNX) were released by: and their article: “Genomic Medicine: Catch The Gene Therapy Wave” published on May 14, 2018 as well as‘s news article titled: “REGENXBIO’s (RGNX) CEO Ken Mills on Q1 2018 Results – Earnings Call Transcript” with publication date: May 12, 2018.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $1.55 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: